Bactiguard Infection Protection "Improving quality of care at - - PowerPoint PPT Presentation

bactiguard infection protection
SMART_READER_LITE
LIVE PREVIEW

Bactiguard Infection Protection "Improving quality of care at - - PowerPoint PPT Presentation

Bactiguard Infection Protection "Improving quality of care at Hospital" Webinar 21 August 2018 Cecilia Edstrm CFO and Business Development 1 2 Antimicrobial Resistance (AMR) European and Global Challenge by 2050 EU: 25 000


slide-1
SLIDE 1

"Improving quality of care at Hospital" Webinar 21 August 2018 Cecilia Edström CFO and Business Development

Bactiguard Infection Protection

1

slide-2
SLIDE 2

2

slide-3
SLIDE 3

3

European and Global Challenge by 2050

Antimicrobial Resistance (AMR)

4.1M 4.7M 392K 317K 392K EU: 25 000 patients die annually Globally: Could be as high as 700 000 2050 => 10 million lives at risk globally

slide-4
SLIDE 4

Source: WHO/HIS/SDS/2016.10 4

HAI frequency

Health care-associated infections

1 in n every ry 10 10 patients affected by health care-associated infections worldwide

slide-5
SLIDE 5

5

Healthcare associated infections

Status in India

  • India is the single largest antibiotics-consuming

country in the world

  • At least 2 million patients affected by Hospital

Acquired Infections every year

  • ¼ of infections occur in the ICUs
  • At least 58,000 babies die each year from

superbugs

  • 60% to 80% of organisms that cause infections

in newborns are resistant to normal antibiotics.

Leading causes of death (Western world)

Rank Cause of death 1 Cardiovascular diseases incl. stroke 2 Cancer 3 Healthcare Associated Infections

Sources: Al Jazeera, The Lancet , apiindia.org and Frontline

slide-6
SLIDE 6

6

  • Preventing healthcare associated infections (HAIs)

has never been more important

  • Every infection prevented is an antibiotic treatment

avoided

Infection prevention and control actions can save millions of lives, every year

According to the World Health Organization (WHO):

The challenge

World Health Organization

slide-7
SLIDE 7

7

Reduce the use of antibiotics Reduce cost Save lives Eliminate healthcare associated infections to:

Bactiguard’s vision

And thereby prevent the spread

  • f multiresistant bacteria
slide-8
SLIDE 8

8

Common sources of infections and sepsis

32% 14% 15% 22% 17%

Urinary tract Blood stream Respiratory tract Surgical site Other BIP Foley Catheter

USA Where does HAI occur?

BIP ETT BIP CVC

Source: Global Sepsis Alliance

slide-9
SLIDE 9

9

Uncoated surface vs. Bactiguard coated surface

Bacterial colonization – causing infections

Uncoated surface Bactiguard coated surface sd

A few seconds

sd

A few hours

sd

A few days A few days A few hours A few seconds

slide-10
SLIDE 10

10

The galvanic effect – effective and safe

The technology

d u a adiu d i r g

  • When in contact with fluids the noble

metals create a galvanic effect

  • The different electro potentials of the

metals create a micro current

  • Preventing microbial adhesion
  • Non-releasing mechanism
  • Effective and safe
slide-11
SLIDE 11

Source: WHO HAI Factsheet, Lakartidningen 2012, CDC

11

9% 34% Sweden HAI Rates EU HAI Rates 7%

30%

  • Top three HAIs in ICUs

➢ VAP – Ventilator Associated Pneumonia ➢ CAUTI – Catheter Associated Urinary Tract Infection ➢ CRBSI – Catheter Related Blood Stream Infection

  • Cost of treating a case of VAP or CRBSI in ICU is in the range of 50-70k Euro
  • Additional length of stay up to additional 22 days in the ICU
  • Mortality for CRBSI and VAP up to 25% and 50% respectively

Low to mid-income HAI Rates

15%

60-90% General ICU ICU General ICU General

Considerable higher HAIs at Intensive care units(ICU)

Compared to hospitals in general

slide-12
SLIDE 12

12

Bactiguard can offer protection against the 3 most common HAIs in the ICU

Why Bactiguard should be standard in every ICU

BIP CVC to prevent CLABSI BIP Foleys to prevent CAUTI BIP ETT to prevent VAP

slide-13
SLIDE 13

Reference: Saint S. et al. Arch Intern Med. 2000; 160:2670–2675.

13

Health economics

slide-14
SLIDE 14
  • Preventing infections has never been more important
  • Address the problem at the source
  • Introduce preventive actions:
  • Focus on total cost of treatment
  • Quality critera in tenders and direct purchases
  • Develop new guidelines
  • Use clinical evidence and data as a reference

14

Concluding remarks

slide-15
SLIDE 15

15

For questions and additional information, please contact: Munish Agarwal, Director India Operation

Cell phone: +91 991 515 89 86

munish.agarwal@bactiguard.se

Cecilia Edström, CFO

Cell phone +46 72-226 23 28 cecilia.edstrom@bactiguard.se @EdstromCecilia

More information available at www.bactiguard.com